Nature's Sunshine Products
Nature's Sunshine Products' revenue rose 5.7% to $480 million in fiscal 2025. Its operating margin was 5.2%, up from 4.4% a year earlier. Free cash flow was $29 million, up 101.3%. It paid out $16 million in dividends and buybacks, 57% of free cash flow. The diluted share count fell 3.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Nature's Sunshine Products does
Nature's Sunshine Products makes and sells herbal and other nutritional supplements and personal care products. Its line of over 800 products covers general health, immune, heart, digestive and weight management products, and items such as aloe vera gel, shampoo and toothpaste. It buys herbs and other raw materials in bulk, then tests, formulates, packages and ships them. Most products are made at its plant in Spanish Fork, Utah, and contract manufacturers make some.
It sells through direct selling: independent consultants who use the products themselves or resell them to consumers, under the Nature's Sunshine Products and Synergy WorldWide brands. It pays these consultants commissions, which it calls volume incentives, based on their own sales and those of their sales organization. It reports four segments by region: Asia, Europe, North America, and Latin America and Other.
The 10-K says that in some markets a significant amount of revenue depends on only a few consultants and their large sales networks. Orders usually ship within 24 hours of payment, so it keeps a considerable inventory of raw materials and finished goods.
Its biggest risks, as it describes them
- Direct selling laws that could restrict or force changes to how it sells in some countries.
- Failing to attract and keep independent consultants, or losing key ones with large sales networks.
- Strict government rules on its products, and difficulty registering them for sale abroad.
- Product liability claims, and obligations arising from what its consultants do.
- Currency swings, and supply chain or manufacturing interruptions.
Income statement
From fiscal 2016 to 2025, earnings per share grew 28.6% a year and net income 44.7% a year, as buybacks cut the share count by 3%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 86 | 60 | 82 | 85 | 94 |
| Debt incl. finance leases | 2 | 1 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −84 | −59 | −82 | −85 | −94 |
| Net debt to EBITDA | −1.8x | −2.2x | −2.7x | −2.5x | −2.4x |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 138.7x | 65.3x | 271.7x | 137.6x | 252.5x |
| Current ratio | 2.1x | 2.3x | 2.2x | 2.4x | 2.3x |
| Quick ratio | 1.4x | 1.2x | 1.3x | 1.5x | 1.4x |
Cash flow
Projections
Project Nature's Sunshine Products' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Nature's Sunshine Products says to expect
- Full year 2026: net sales and adjusted EBITDA
Reflecting the impact of a stronger U.S. dollar and recent challenges in the China market, Nature's Sunshine now expects full year 2026 net sales to range between $460 and $470 million ($490 and $500 million prior). Adjusted EBITDA is now expected to range between $44 and $48 million ($48 and $52 million prior).
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 2 insiders bought $5.5 million of Nature's Sunshine Products shares on the open market, and 5 insiders sold $1.9 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | Prescott Group Capital Management L.l.c.10% owner | Bought | 291,666 | $9.77 | $2.8 million | Form 4 |
| Aug 17, 2026 | Phil Frohlich10% owner | Bought | 20,000 | $14.69 | $293,800 | Form 4 |
| Aug 10, 2026 | Prescott Group Capital Management L.l.c.10% owner | Bought | 40,876 | $15.84 | $647,539 | Form 4 |
| Aug 7, 2026 | Prescott Group Capital Management L.l.c.10% owner | Bought | 96,000 | $16.63 | $1.6 million | Form 4 |
| Aug 6, 2026 | Prescott Group Capital Management L.l.c.10% owner | Bought | 4,513 | $16.57 | $74,793 | Form 4 |
| Jun 12, 2026 | Kevin R. HerbertEVP & President, North America | Sold | 2,000 | $20.68 | $41,364 | Form 4 |
| Jun 5, 2026 | Bryant J YatesEVP & President, Europe | Sold | 11,968 | $19.90 | $238,163 | Form 4 |
| Jun 1, 2026 | Daniel C NormanEVP & President, Asia | Sold | 9,713 | $20.64 | $200,476 | Form 4 |
| May 21, 2026 | Nathan G BrowerEVP, General Counsel | Sold | 12,015 | $21.84 | $262,408 | Form 4 |
| Mar 13, 2026 | Bryant J YatesEVP & President, Europe | Sold | 19,516 | $24.35 | $475,215 | Form 4 |
| Mar 13, 2026 | Daniel C NormanEVP & President, Asia | Sold | 15,383 | $24.52 | $377,191 | Form 4 |
| Mar 13, 2026 | Jonathan David LanoySVP, Chief Accounting Officer | Sold | 4,000 | $24.70 | $98,800 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 5 of 9 | 7 of 9 |
| Rule of 40 | 12.4% | 5.2% | 11.7% |
| Altman Z'' | 5.35 | 6.04 | 5.82 |
| Accruals ratio | −10.9% | −7.2% | −6.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Pass | Pass |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 7 of 9 | 5 of 9 | 7 of 9 |
Compare
Put Nature's Sunshine Products side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nature's Sunshine Products | FY25 | 5.7% | 5.2% | 6.0% | 23.6% | −2.4x | 7 | |
| The Honest Company | FY25 | −1.9% | −5.0% | 3.7% | — | — | — | Compare |
| USANA Health Sciences | FY25 | 8.3% | 4.0% | 0.9% | — | — | — | Compare |
| Nu Skin | FY25 | −14.3% | 4.4% | 3.1% | 6.5% | −0.1x | 7 | Compare |
| e.l.f. Beauty | FY26 | 24.6% | 4.5% | 11.6% | 3.8% | 3.6x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 341 | 342 | 365 | 362 | 385 | 444 | 422 | 445 | 454 | 480 |
| Revenue growth | 5.1% | 0.3% | 6.7% | −0.7% | 6.3% | 15.3% | −5.0% | 5.5% | 2.0% | 5.7% |
| Gross profit | 250 | 251 | 269 | 268 | 284 | 329 | 300 | 321 | 325 | 348 |
| Research and development | 3 | 3 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | 2 |
| Operating income | 10 | 1 | 5 | 16 | 22 | 35 | 16 | 19 | 20 | 25 |
| Net income | 1 | −14 | −1 | 7 | 23 | 30 | −0 | 15 | 8 | 20 |
| Diluted EPS (US$) | 0.11 | −0.69 | −0.04 | 0.34 | 1.07 | 1.42 | −0.02 | 0.77 | 0.40 | 1.06 |
| Diluted shares (millions) | 19 | 19 | 19 | 20 | 20 | 20 | 19 | 20 | 19 | 18 |
| Cash flow | ||||||||||
| Cash from operations | 3 | 10 | 22 | 8 | 38 | 35 | 1 | 41 | 25 | 35 |
| Capital expenditure | 11 | 6 | 5 | 5 | 5 | 7 | 8 | 10 | 11 | 6 |
| Free cash flow | −8 | 5 | 17 | 3 | 33 | 28 | −7 | 31 | 14 | 29 |
| Dividends paid | 8 | 2 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 7 | 14 | 6 | 9 | 16 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 2 | 2 | 2 | 4 | 4 | 3 | 5 | 5 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 32 | 43 | 51 | 54 | 92 | 86 | 60 | 82 | 85 | 94 |
| Debt incl. finance leases | — | — | — | 0 | 4 | 2 | 1 | 0 | 0 | 0 |
| Total assets | 206 | 195 | 193 | 213 | 250 | 259 | 230 | 250 | 241 | 261 |
| Total liabilities | 73 | 76 | 72 | 84 | 92 | 98 | 83 | 90 | 80 | 100 |
| Shareholders' equity | 132 | 120 | 121 | 129 | 157 | 161 | 147 | 160 | 161 | 162 |
| Margins and ratios | ||||||||||
| Gross margin | 73.3% | 73.4% | 73.8% | 74.1% | 73.7% | 74.0% | 71.0% | 72.1% | 71.5% | 72.4% |
| Operating margin | 2.9% | 0.4% | 1.5% | 4.5% | 5.6% | 7.8% | 3.9% | 4.2% | 4.4% | 5.2% |
| Net margin | 0.2% | −4.0% | −0.3% | 1.9% | 6.0% | 6.8% | −0.1% | 3.4% | 1.7% | 4.1% |
| Free cash flow margin | −2.2% | 1.5% | 4.7% | 0.9% | 8.5% | 6.3% | −1.6% | 6.9% | 3.1% | 6.0% |
| Rule of 40 (growth + FCF margin) | 2.8% | 1.7% | 11.3% | 0.2% | 14.8% | 21.6% | −6.6% | 12.4% | 5.2% | 11.7% |
| Return on capital | — | — | — | — | 29.7% | 44.9% | 9.8% | 18.4% | 13.1% | 23.6% |
| Return on equity | 0.5% | −11.0% | −1.0% | 5.5% | 16.0% | 19.0% | −0.2% | 9.8% | 4.8% | 12.1% |
| Return on assets | 0.3% | −6.9% | −0.6% | 3.4% | 9.9% | 11.9% | −0.2% | 6.3% | 3.1% | 7.8% |
| Net debt to EBITDA | — | — | — | −2.0x | −2.7x | −1.8x | −2.2x | −2.7x | −2.5x | −2.4x |